Abstract

Regarding the side effects of drugs available for the treatment of colorectal cancer (CRC), agents will be grouped according to the mode of action and the respective toxicities in cytotoxic agents (fluoropyrimidines (5-FU, capecitabine), TAS 102, irinotecan, and oxaliplatin), antiangiogenic agents (the vascular endothelial growth factor (VEGF) antibody bevacizumab, the VEGF receptors (VEGFR) 1 and 2 fusion protein aflibercept, the VEGF receptor 2 antibody ramucirumab, and the multitarget tyrosine kinase inhibitor regorafenib), and epidermal growth factor receptor (EGFR)-targeting agents (cetuximab and panitumumab).

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call